Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis

Cytokine

Volumn 53, Issue 1, 2011, Pages 100-106

  Campanelli, Rita ^a   Rosti, Vittorio ^a   Villani, Laura ^a   Castagno, Marta ^b   Moretti, Enza ^b   Bonetti, Elisa ^a   Bergamaschi, Gaetano ^a   Balduini, Alessandra ^b   Barosi, Giovanni ^a   Massa, Margherita ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

CCL64 cell line; Myeloproliferative diseases; Primary myelofibrosis; Transforming growth factor beta

Indexed keywords

ISOPROTEIN; JANUS KINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; BIOLOGICAL ACTIVITY; CELL COMPARTMENTALIZATION; CELL COUNT; CELL DIFFERENTIATION; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MYELOFIBROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SPLEEN CELL; SPLENECTOMY; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BONE MARROW; CELL LINE; CELL PROLIFERATION; HUMANS; MIDDLE AGED; MINK; PRIMARY MYELOFIBROSIS; SPLEEN; SUBCELLULAR FRACTIONS; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 78349307056     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2010.07.427     Document Type: Article

References (37)

1. Fortunel N.O., Hatzfeld A., Hatzfeld J.A. Transforming growth factor-β: pleiotropic role in the regulation of haematopoiesis. Blood 2000, 96:2022-2036.
2. Dong M., Blobe G.C. Role of Transforming growth factor-β in haematologic malignancies. Blood 2006, 107:4589-4596.
3. Chabanon A., Desterke C., Rodenburger E., Clay D., Guerton B., Boutin L., et al. A cross-talk between stromal cell-derived factor-1 and transforming growth factor-β controls the quiescence/cycling switch of CD34+ progenitors through FoxO3 and mammalian target of rapamycin. Stem Cells 2008, 26:3150-3161.
4. Wright N., Lain de Lera T., Garcia-Moruja C., Lillo R., Garcia-Sanchez F., Caruz A., et al. Transforming growth factor-β1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 2003, 102:1978-1984.
5. Basu S., Broxmeyer H.E. Transforming growth factor-β1 modulates responses of CD34+ cord blood cells to stromal cell-derived factor-1/CXCL12. Blood 2005, 106:485-493.
6. Verrecchia F., Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol 2007, 13:3056-3062.
7. Le Bousse-Kerdiles M.C., Martyre M.C., Samson M. Cellular and molecular mechanisms underlying bone marrow and liver fibrosis: a review. Eur Cytokine Netw 2008, 19:69-80.
8. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Werning G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
9. Barosi G., Viarengo G.L., Pecci A., Rosti V., Piaggio G., Marchetti M., et al. Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood 2001, 98:3249-3255.
10. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Onc 1999, 17:2954-2970.
11. low mice). Blood 2002, 100:1123-1132.
12. Vannucchi A.M., Bianchi L., Paoletti F., Pancrazzi A., Torre E., Nishikawa M., et al. A pathologic pathway linking thrombopoietin, GATA-1 and TGF-β1 in the development of myelofibrosis. Blood 2005, 105:3493-3501.
13. Le Bousse-Kerdiles M.C., Chevillard S., Charpentier A., Romquin N., Clay D., Smadja-Joffe F., et al. Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996, 88:4534-4546.
14. Hemavathy K.C., Chang T.H., Zhang H., Charles W., Goldberg A., Aithal S., et al. Reduced expression of TGFβ1RII in agnogenic myeloid metaplasia is not due to mutation or methylation. Leukemia Res 2006, 30:47-53.
15. Martyre M.C., Romquin N., Le Bousse-Kerdiles M.C., Chevillard S., Benyahia B., Dupriez B., et al. Transforming growth factor-β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Hematol 1994, 88:9-16.
16. Wang J.C., Chang T.H., Goldberg A., Novetsky A.D., Lichter S., Lipton J. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Exp Hematol 2006, 34:1617-1623.
17. Ciurea S.O., Merchant D., Mahmud N., Ishii T., Zhao Y., Hu W., et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 2007, 110:986-993.
18. Rameshwar P., Denny T.N., Stein D., Gascòn P. Monocyte adhesion in patients with bone marrow fibrosis is required fort he production of fibrogenic cytokines. J Immunol 1994, 153:2819-2830.
19. Martyre M.C., Magdalena H., Bracket M.C., Laine-Bidron C., Calve F. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-β in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1991, 77:80-86.
20. Zauli G., Visani G., Catani L., Vianelli N., Gugliotta L., Capitani S. Reduced responsiveness of bone marrow megakaryocyte progenitors to platelet-derived transforming growth factor β1, produced in normal amount, in patients with essential thrombocythemia. Br J Haematology 1993, 83:14-20.
21. Rameshwar P., Chang V.T., Thacker U.F., Gascon P. Systemic transforming growth factor-beta in patients with bone marrow fibrosis-pathophysiological implications. Am J Hematol 1998, 59:133-142.
22. Lippert E., Boissinot M., Kralovics R., Girodon F., Dobo I., Praloran V., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108:1865-1867.
23. Bock O., Loch G., Schade U., von Wasielwski R., Schluè J., Kreipe H. Aberrant expression of transforming growth factorβ-1 (TGFβ-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders. J Pathol 2005, 205:548-557.
24. Barosi G., Ambrosetti A., Finelli C., Grossi A., Leoni P., Liberato N.L., et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999, 104:730-737.
25. Goulis J., Chau T.N., Jordan S., Mehta A.B., Watkinson A., Rolles K., et al. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. Gut 1999, 44:754-758.
26. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
27. Berlin N.I. Diagnosis and classification of the polycythemias. Semin Hematol 1975, 12:339-351.
28. Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 1986, 23:177-182.
29. Balduini A., Pecci A., Lova P., Arezzi N., Marseglia C., Bellora F., et al. Expression, activation and subcellular localization of the Rap1 GTPase in cord blood-derived human megakaryocytes. Exp Cell Res 2004, 300:84-93.
30. Danielpour D., Dart L.L., Flanders K.C., Roberts A.B., Sporn M.B. Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J Cell Physiol 1989, 138:79-86.
31. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
32. Garrigue-Antar L., Barbieux I., Lieubeau B., Boisteau O., Gregoire M. Optimisation of CCL64-based bioassay for TGF-β. J Immunol Methods 1995, 186:267-274.
33. Bennet A.L., Chao C.C., Hu S., Buchwald D., Fagioli L.R., Schur P.H., et al. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 1997, 17:160-166.
34. Grainger D.J., Mosedale D.E., Metcalfe J.C. TGF-β in blood: a complex problem. Cytokine Growth Factor Rev 2000, 11:133-145.
35. Wakefield L.M., Letterio J.J., Chen T., Danielpour D., Allison R.S.H., Pai L.H., et al. Transforming Growth Factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res 1995, 1:129-136.
36. Grainger D.J., Mosedale D.E., Metcalfe J.C., Weissberg P.L., Kemp P.R. Active and acid-activable TGF-β in human sera, platelets and plasma. Clin Chim Acta 1995, 235:11-31.
37. Murphy-Ullrich J.E., Schultz-Cherry S., Hook M. Transforming growth factor-beta complexes with thrombospondin. Mol Biol Cell 1992, 3:181-188.